Investors Purchase Large Volume of Call Options on Recursion Pharmaceuticals (NASDAQ:RXRX)

Posted by Francis Steltz on Sep 17th, 2026

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) was the target of some unusual options trading on Thursday. Stock traders bought 25,291 call options on the company. This represents an increase of approximately 50% compared to the average daily volume of 16,872 call options.

Recursion Pharmaceuticals Stock Up 11.1%

Shares of NASDAQ:RXRX traded up $0.35 during midday trading on Thursday, reaching $3.54. 22,899,929 shares of the company were exchanged, compared to its average volume of 17,901,400. The firm has a market cap of $1.90 billion, a PE ratio of -3.40 and a beta of 1.07. Recursion Pharmaceuticals has a fifty-two week low of $2.77 and a fifty-two week high of $7.18. The stock has a fifty day simple moving average of $3.26 and a two-hundred day simple moving average of $3.32. The company has a quick ratio of 5.03, a current ratio of 5.03 and a debt-to-equity ratio of 0.01.

Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.01). Recursion Pharmaceuticals had a negative return on equity of 50.41% and a negative net margin of 945.94%.The firm had revenue of $7.67 million for the quarter, compared to the consensus estimate of $10.97 million. During the same quarter last year, the company posted ($0.41) EPS. As a group, sell-side analysts forecast that Recursion Pharmaceuticals will post -0.92 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have commented on RXRX. Morgan Stanley set a $5.30 target price on shares of Recursion Pharmaceuticals in a research note on Monday, August 17th. Wall Street Zen raised shares of Recursion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, August 29th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Friday, July 17th. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $8.06.

View Our Latest Research Report on RXRX

Insider Activity

In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 40,000 shares of the firm’s stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $3.96, for a total transaction of $158,400.00. Following the transaction, the director owned 6,218,287 shares in the company, valued at approximately $24,624,416.52. This trade represents a 0.64% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Najat Khan sold 22,408 shares of the business’s stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $3.52, for a total value of $78,876.16. Following the transaction, the chief executive officer owned 2,072,890 shares of the company’s stock, valued at $7,296,572.80. The trade was a 1.07% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 122,408 shares of company stock worth $434,976 in the last three months. Insiders own 6.65% of the company’s stock.

Institutional Investors Weigh In On Recursion Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Hsbc Holdings PLC raised its holdings in shares of Recursion Pharmaceuticals by 537.3% in the fourth quarter. Hsbc Holdings PLC now owns 818,316 shares of the company’s stock valued at $3,367,000 after purchasing an additional 689,903 shares during the last quarter. Lingotto Investment Management LLP boosted its holdings in Recursion Pharmaceuticals by 34.2% during the fourth quarter. Lingotto Investment Management LLP now owns 4,931,057 shares of the company’s stock worth $20,168,000 after purchasing an additional 1,255,980 shares during the last quarter. Renaissance Technologies LLC acquired a new position in Recursion Pharmaceuticals during the first quarter worth $7,370,000. Bank of New York Mellon Corp grew its position in Recursion Pharmaceuticals by 29.3% in the first quarter. Bank of New York Mellon Corp now owns 1,462,631 shares of the company’s stock valued at $4,490,000 after purchasing an additional 331,048 shares in the last quarter. Finally, Norges Bank bought a new position in Recursion Pharmaceuticals in the fourth quarter valued at $23,473,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

(Get Free Report)

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biotechnology company that uses artificial intelligence, automation, and large-scale biological experimentation to accelerate the discovery and development of medicines. Its technology platform, known as the Recursion Operating System, integrates data from biology, chemistry, imaging, and machine learning to identify potential drug candidates and better understand disease biology.

The company develops therapies for areas including oncology, rare diseases, and neurological disorders.